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Abstract
Background: There is ample evidence that Hsp70 takes part in the progress of coronary heart disease (CHD). This implies
that genetic variants of Hsp70 genes such as HSPA8 (HSC70) gene might contribute to the development of CHD. The
present study aimed to investigate whether certain genetic variants of HSPA8 gene are associated with CHD in Han Chinese
people.
Methodology/Principal Findings: A total of 2006 subjects (1003 CHD cases and 1003 age- and sex- matched healthy
controls) were recruited. Genetic variants in the HSPA8 gene were identified by sequencing of the gene in 60 unrelated
Chinese. Four tag single nucleotide polymorphisms (tagSNPs) (rs2236659, rs2276077, rs10892958, and rs1461496) were
selected and genotyped. The function of the significant SNP was evaluated using luciferase reporter assays in two cell lines.
By sequencing the promoter and all exons and introns of the HSPA8 gene, 23 genetic variants were identified. One promoter
SNP rs2236659 was associated with susceptibility to CHD. Carriers of the ‘‘C’’ allele of rs2236659 had decreased CHD risk
with odds ratio (OR) of 0.78 (95% CI: 0.62, 0.98; P=0.033) after adjustment for conventional risk factors. Haplotype analyses
indicated that haplotype GCGC contributed to a lower CHD risk (OR=0.78, 95% CI: 0.65, 0.93; P=0.006) compared with the
common haplotype AGGT. In a transfection assay, the C allele of rs2236659 showed a 37–40% increase in luciferase
expression of the reporter gene luciferase in endothelial and non-endothelial cells compared with the T allele.
Conclusions/Significance: These findings suggest that genetic variants in HSPA8 gene (especially promoter SNP rs2236659)
contribute to the CHD susceptibility by affecting its expression level.
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Introduction
Coronary heart disease (CHD) is a complex disease with high
morbidity and mortality. Very little is known about its genetic
etiology. Heat shock protein 70 (HSP70), as a dominant chaperone
in the HSPs families, can help in the assembly of newly synthesized
proteins, in protein transport, and in the removal of damaged
proteins [1]. In humans, the HSP70kDa family comprises 13
members, some of which show constitutive expression while others
are stress inducible [2]. These isoforms have highly homogenous
structure. They are all composed of a conserved ATPase domain,
a peptide-binding domain, a middle region with protease sensitive
sites, and a C-terminal domain[3,4]. For instance, HSPA8,
previously referred to as HSP73 or HSC70, shares 86% amino
acid homology to inducible HSPA1A[3]. Consistent with their
homogenous structure, these proteins have distinct but overlap-
ping functions[3]. Thus both stress-inducible Hsp70 and consti-
tutively expressed HSPA8 can perform some similar functions and
are capable of protecting cardiac muscle cells against injuries like
an oxidative challenge[5,6]. There is much evidence indicating
that Hsp70 can take part in the progress of CHD[7–9]. A previous
study from our laboratory also demonstrated that genetic variants
in the HSPA1A gene may be novel genetic risk markers for
CHD[10]. Based on their high degree of structural homology and
similar function in protecting against injuries in cardiac muscle
cell, it is conceivable that the main constitutively-expressed
member of the HSP70 family, HSPA8 might also be involved in
the development of CHD and that single nucleotide polymor-
phisms (SNPs) and haplotypes of this gene may be associated with
CHD and contribute to CHD susceptibility.
To test this hypothesis, we first sequenced and identified all
SNPs in the HSPA8 gene in 60 unrelated Han Chinese. We then
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9684selected 4 tagging SNPs (tagSNPs) to identify potential genetic
markers of this gene for CHD susceptibility in a case-control study
comprised of 1,003 CHD cases and 1,003 age- and sex- frequency
matched controls in a Chinese population. We also examined the
function of the SNPs associated with CHD susceptibility by
performing a reporter gene luciferase activity assay in two types of
cell lines.
Results
SNPs Identification in the HSPA8 Gene in Han Chinese
In total we found 23 genetic variants in HSPA8 gene with minor
allele frequency (MAF) from 5.0% to 45.0% (Table 1). Among
those, 6 novel SNPs had not been reported previously, including
301 c/g and 395 c/g (intron 1), 1255 t/c (intron 2), 1671 c/t
(intron 3), 2692 gactc/– and 2716 ca/– (intron 5); The remaining
17 SNPs have been reported in NCBI as shown in Table 1
(http://www.ncbi.nlm.nih.gov/genome). SNP rs11218942 (G .
T. C) is triallelic and was not analyzed in further linkage
disequilibrium analysis and tagSNPs selection.
Selection of tagSNPs in HSPA8 Gene
Based on the above sequencing data, linkage disequilibrium
analysis results showed that all detected SNPs located in the same
haploblock (Figure 1). The htSNPer1.0 software was used to pick
out the tagSNPs[11], and finally four SNPs were selected
as tagSNPs, including rs2236660, rs2236658, rs10892958 and
rs1461496 (Figure 2). Because the sequences around the SNPs
rs2236660 and rs2236658 are rich in GC and not suitable to be
detected by TaqMan SNP allelic discrimination assay, we selected
the other two SNPs rs2236659 and rs2276077, which are in high
linkage with rs2236660 and rs2236658 for further analysis.
General Characteristics of the Subjects
The general characteristics of the CHD cases and controls have
been described in a previous study[12] and are summarized in
Table 2. CHD patients had a higher prevalence of conventional
vascular risk factors, including smoking, non-drinking, history of
hypertension and diabetes mellitus, family history of CHD and
higher level of FBG, whereas TC level in patients were surprisingly
lower than in controls probably due to cholesterol-lowering
treatment in the cases.
HSPA8 Genotypes and CHD Risk
The genotype frequencies of the four studied SNPs in HSPA8
polymorphisms are summarized in Table 3. The distributions of
SNPs rs2236659, rs2276077, rs10892958 and rs1461496 did not
depart from the Hardy-Weinberg equilibrium in control group
(P=0.73, 0.62, 0.79 and 0.22 respectively). There was significant
difference in genotype distribution of rs2236659 between CHD
and controls. Adjustment for the conventional risk factors such as
age, sex, pack-years of smoking, drinking, activity, hypertension,
DM and family history of CHD did not appreciably alter the
results. Compared with TT genotype of rs2236659, subjects
with C allele had lower risk of CHD after adjustment for the
conventional risk factors above (Crude odds ratio (OR)=0.83,
95% CI: 0.69, 1.00; P=0.049 and adjusted OR=0.78, 95%
confidence interval (CI): 0.62, 0.98; P=0.033 respectively)
(Table 3). Stratified analysis according to age (#60 years and
.60 years), sex and smoking status indicated that subjects with C
allele of rs2236659 in men, older (.60 years) or smokers
subgroups had significant lower risk of CHD. However in females,
younger or non-smokers subgroups there were no significant
differences. Further analysis indicated that there were no
interactions between SNP rs2236659 and above factors respec-
tively (data not shown). There were no significant differences
between CHD and control group in SNPs of rs2276077,
rs10892958 and rs1461496 before or after adjusting for conven-
tional risk factors (P .0.05).
Haplotype Associations with CHD Risk
All the pairwise LD measure D’ of the four investigated tagSNPs
in the HSPA8 gene ranged from 0.90 to 0.96 (data not shown). A
total of 14 and 12 haplotypes were estimated in the CHD and
control groups respectively by using PHASE 2.0 software to
reconstruct haplotypes based on the observed genotypes[13].
Among these, 5 haplotypes of AGGT, GCGT, GCGC, GGAT and
GGGT were .1.0% (from left to right the order of polymorphic
bases in haplotype is rs1461496, rs10892958, rs2276077, and
rs2236659). The associations between the common haplotypes
(covering 96.95% and 98.16% of allelic variance in CHD and
controls, respectively) encompassing HSPA8 polymorphisms and
CHD risk were also examined. Compared with the highest-
frequency haplotype of AGGT, the GCGC haplotype had 22%
lower risk of CHD (OR=0.78, 95% CI: 0.65, 0.93; P=0.006).
However, haplotype GCGT, which is only different from GCGC in
rs2236659, had no significant difference compared with AGGT
(OR=1.00, 95% CI: 0.85, 1.17; P=0.958), confirming the results
Table 1. Variants discovered by sequencing all HSPA8 exons
and introns and 1 Kb upstream of transcript start site in 60
unrelated Chinese.
Variants Position
*
Gene
pos. Alleles
MAF
(%) Heterozygosity
rs11218942 2926 promoter G . T. C1 3 . 30 . 4 8
rs2236660 2703 promoter T . C1 4 . 2 0 . 2 4
rs2236659 2357 promoter T . C1 5 . 8 0 . 2 7
rs2236658 2308 promoter A . G3 5 . 8 0 . 4 6
rs2276077 8 59 UTR G . A1 9 . 2 0 . 3 1
rs2276075 23 59 UTR C . T1 9 . 2 0 . 3 1
rs1136141 48 59 UTR C . T5 . 0 0 . 0 9
rs2276074 49 59 UTR C . G3 0 . 0 0 . 4 2
New1
{ 301 intron1 C . G1 9 . 2 0 . 3 1
New2
{ 395 intron1 C . G1 7 . 5 0 . 2 9
rs11218941 416 intron1 T . C3 7 . 5 0 . 4 7
rs4935825 460 intron1 T . G1 . 7 0 . 0 3
rs11823704 647 intron1 G . T1 8 . 3 0 . 3 0
rs10892958 702 intron1 G . C4 0 . 4 0 . 4 8
New3
{ 1255 intron2 T . C2 0 . 0 0 . 3 2
New4
{ 1671 intron3 C . T1 2 . 5 0 . 2 2
New5
{ 2692 intron5 Ins GACTC 12.5 0.22
New6
{ 2716 intron5 Ins CA 5.8 0.11
rs1461496 3201 intron6 C . T4 4 . 5 0 . 4 9
rs1064585 3418 exon7 A . C5 . 8 0 . 1 1
rs4936770 3950 intron8 A . G4 5 . 0 0 . 4 9
rs3763897 4191 intron8 T . A1 1 . 7 0 . 2 1
rs4802 4203 exon9 C . T4 5 . 0 0 . 4 9
*Reference the transcription start code as +1.
{Novel SNP not reported in public database before.
doi:10.1371/journal.pone.0009684.t001
HSPA8 Variants and CHD Risk
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lower risk of CHD (Table 4).
HSPA8 Promoter Region Carrying the 2357C (rs2226659)
Leads to Higher Expression in a Reporter Assay
In order to understand the functional significance of the-357 T/
C change, we used a reporter assay with luciferase. As shown in
Figure 3, relative luciferase expression driven by the T-C-G
containing promoter were 37–40% higher than that by the
haplotype T-T-G containing promoter in the two types of cell lines
(P=0.008 for HBE and 0.046 for HUVEC). Because the two
haplotypes of T-C-G and T-T-G are only different in -357T/C,
these results suggested that the -357C variant (rs2236659) had a
higher promoter activity than -357T allele. Similar results were
obtained for the T-T-A haplotype when comparing with
haplotypes T-T-G or C-C-G in HBE; however, there were no
significant differences observed in HUVEC cells
Discussion
Our study is the first one to examine the associations of variants
of a constitutively expressed member of the HSP70 family, HSPA8
and CHD susceptibility. Subjects with the C allele of rs2236659
had lower risk of CHD independent of other conventional risk
factors. Further functional study in a cell reporter assay suggested
that this association might be due to the increased promoter
activity of the C allele of rs2236659 which may result in higher
levels of expression of this HSPA8 protein.
HSPA8 is constitutively expressed and only mildly induced
during stress situations[14]. It plays an important role in folding
protein during their synthesis, transporting protein across
membranes, regulating stress response and it is also involved in
cell survival[4,15]. In cardiac muscle cells, overexpression of
HSPA8 attenuated oxidative injuries and enhanced cell surviv-
al[5]. This implies that HSPA8 might participate in the progress of
CHD since it is believed that oxidative injuries are involved in the
etiology of CHD[16]. Variants of HSPA8 gene could affect HSPA8
levels and/or function. HSPA8 might take part in the develop-
ment of CHD by two ways. First, as mentioned above it is believed
that reactive oxygen species (ROS) are involved in the etiology of
CHD[16–18]. This Hsp could protect against endogenous or
exogenously generated ROS[5] and thus contribute to the
progression of CHD. Second, this protein has also been reported
to protect against hypoxia-induced apoptosis in hypoxia-induced
apoptosis-resistant macrophages[19] and in the control of
apoptosis during embryogenesis[20]. Other studies have found
Figure 1. Linkage disequilibrium (D’ and r
2) between single nucleotide polymorphisms in HSPA8 gene. Based on the data on the
resequencing of the HSPA8 gene, a total of 22 single nucleotide polymorphisms were analyzed by JLIN software to analyze linkage disequilibrium (D’
and r
2) between SNPs.
doi:10.1371/journal.pone.0009684.g001
HSPA8 Variants and CHD Risk
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apoptosis signaling and that its overexpression results in resistance
against stress-induced caspase activation[4,21]. Although to our
knowledge no previous studies have investigated the role of
HSPA8 in endothelium cells apoptosis, it might protect endothe-
lium cells against apoptosis, which is believed to be the initiating
event of atherogenesis and plays a crucial role in the transi-
tion from a stable endothelialized plaque to plaque erosion and
thrombosis[22].
SNPs in the promoter of the HSPA8 gene might affect its level of
transcription and then lead to similar changes at the protein level.
The SNP rs2236659 locates 357 bp upstream of transcriptional
start code. In silico analysis using bioinformatics softwares of
Alibaba2.0 (Niels Grabe, http://www.gene-regulation.com/pub/
programs/alibaba2/) and TESS program (http://agave.humgen.
upenn.edu/utess/tess), predicts that the C allele has stronger
binding capacity with transcriptional factor sp1 when compared
with the T allele. Consistent with the computation, our study
confirmed that C allele of SNP rs2236659 leads to an increase in
promoter activity and probably heightens synthesis level of the
corresponding HSPA8 protein which could decreases the risk of
CHD. By using global expression data available from human
lymphoblastoid cell lines[23], we did not find any evidence that
rs2236659 directly influences HSPA8 expression. However,
further studies conducted in cardiac tissues, vascular smooth
muscle and/or endothelial cells would be necessary to draw
conclusions about the possible effects of the rs2236659 SNP on
HSPA8 expression.
Several strengths of this study should be acknowledged. First,
our population is racially homogeneous (all Han Chinese), which
weakens the possible biases from population stratification. In
addition, the findings from case-control association study were
confirmed by detailed functional assays in both endothelial and
nonendothelial cell lines strengthened the association of the HSPA8
gene variations and CHD. However, three major limitations
should also be mentioned. Firstly, like all case-control studies,
selection bias (inclusion of patients surviving CHD) may exist and
might influence interpretation of the results. Secondly, the controls
selected without performing coronary angiography might include
some false negative cases. However, because the prevalence of
Figure 2. Construction of haplotype and tagging SNPs selection in HSPA8 gene. A total of 22 single nucleotide polymorphisms (SNPs) were
analyzed by htSNPer1.0 software to select tagSNPs. 1.0 indicated rs2236660 and 22.0, the last SNP rs4802. The results showed that rs2236660,
rs2236658, rs10892958 and rs1461496 were selected for tagSNPs.
doi:10.1371/journal.pone.0009684.g002
Table 2. General characteristics of CHD cases and controls
*.
Variables
Cases
(n=1003)
Controls
(n=1003) P Value
Sex (male/female) 638/365
(63.6/36.4)
637/366
(63.4/36.6)
0.94
Age (y) 59.7 (8.8) 59.5 (8.5) 0.31
Systolic blood pressure (mmHg) 134.6 (24.6) 131.6 (21.1) 0.004
Diastolic blood pressure (mmHg) 82.0 (14.4) 82.5 (11.1) 0.45
Body mass index 24.46 (3.51) 24.41 (3.37) 0.77
FBG (mmol/L) 6.66 (3.63) 5.32 (2.00) ,0.01
TC (mmol/L) 4.50 (1.05) 5.08 (1.30) ,0.01
TG (mmol/L) 1.73 (1.24) 1.69 (1.31) 0.45
Smoking (no/past or current) 435/564
(43.5/56.5)
535/468
(53.3/46.7)
,0.01
Smoking index (pack-year) ,0.01
0 435(43.5) 535(53.3)
0–31 281(28.1) 273(27.2)
31- 283(28.4) 195(19.5)
Drinking (no/yes) 733/266
(73.4/26.6)
681/316
(68.3/31.7)
0.01
Past history
Hypertension 705(70.4) 342(34.9) ,0.01
Diabetes mellitus 277(27.8) 63(6.5) ,0.01
Family history of
cardiovascular disease
111(11.1) 31(3.1) ,0.01
*Data are means (standard deviation) for continuous variables and n (%) for
categorical variables.
doi:10.1371/journal.pone.0009684.t002
HSPA8 Variants and CHD Risk
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ECG and no clinical symptoms before enrollment, the false
negative cases in the controls are likely to be rare. Finally,
replication is the best way to validate an association, however, the
present matched case-control study is well designed and had
enough power (.80%) to detect SNPs with risk ratios .1.35, 1.30,
and 1.25, given an a of 0.05 and allele frequencies of 0.1, 0.3, and
0.5, respectively. In addition, our detailed functional assays
conducted in both endothelial and nonendothelial cell lines
confirmed and strengthened the associations of the HSPA8 gene
variations and CHD. However, these associations still need to be
validated in other ethnic groups.
In summary, our case-control study and reporter assays results
suggest that variants in HSPA8 gene contribute to CHD
susceptibility. Future studies are needed to validate these findings
and further investigate potential mechanisms underlying the links
between variations of HSPA8 gene and CHD risk.
Materials and Methods
Screening for SNPs in HSPA8 Gene
DNA samples extracted from whole blood of 60 randomly
selected healthy Han Chinese (28 males and 32 females) were used
to identify SNPs in HSPA8 gene (GenBank accession
NM_006597.3). Resequencing region included all HSPA8 exons
and introns and 1 Kb upstream of the transcript start site.
Genomic DNA was amplified and then purified using the ethanol/
NaAc method. The PCR products were used as templates
for sequencing reactions with the BigDye Terminator kit v3.1
(Applied Biosystems, Foster City, CA, USA). Purified sequencing
reactions were run on an ABI 3100 genetic analyzer. Sequence
analysis, SNP detection, and genotype were performed using
Sequencing Analysis 5.1.1 and DNAStar software. All primers and
reaction conditions are displayed in Table S1.
Human Subjects
The study design for this investigation has been described
earlier [12]. Briefly, the study population was composed of 1,003
Table 3. Analysis of associations between the HSPA8 polymorphisms and risk of CHD.
Cases Controls Crude OR (95% CI) Adjusted OR (95% CI)*
Genotype N (%) N (%)
rs1461496
GG 321 33.3 341 34.4 1.00 1.00
AG 435 45.1 464 46.9 1.00(0.82, 1.22) 1.01(0.79, 1.29)
AA 209 21.7 185 18.7 1.20(0.94, 1.54) 1.19(0.88, 1.62)
AG+AA 644 66.8 649 65.6 1.05(0.87,1.27) 1.06(0.84, 1.34)
rs10892958
GG 336 34.6 305 30.7 1.00 1.00
GC 453 46.7 495 49.8 0.83(0.68, 1.02) 0.79(0.62, 1.02)
CC 181 18.7 194 19.5 0.85(0.66, 1.09) 0.82(0.60, 1.13)
GC+CC 634 65.4 689 69.3 0.84(0.69, 1.01) 0.80(0.64, 1.01)
rs2276077
GG 721 74.6 749 75.5 1.00 1.00
AG 228 23.6 228 23.0 1.04(0.84, 1.28) 0.99(0.76, 1.28)
AA 18 1.9 15 1.5 1.25(0.62, 2.49) 2.00(0.81, 4.99)
AG+AA 246 25.5 243 24.5 1.05(0.86,1.29) 1.03(0.81,1.33)
rs2236659
TT 652 68.0 624 63.7 1.00 1.00
CT 267 27.8 313 32.0 0.82(0.67, 0.99) { 0.76(0.59, 0.97) {
CC 40 4.2 42 4.3 0.91(0.58, 1.43) 0.93(0.54, 1.61)
CT+CC 307 32.0 355 36.3 0.83(0.69, 1.00) 1 0.78(0.62, 0.98) ||
*Adjusted for age, sex, pack-years of smoking, drinking, activity, hypertension, diabetes milletus and family history of CHD.
{P=0.043, { P=0.025, 1 P=0.049, and ||P=0.033 respectively when compared with TT genotype of rs2236659.
doi:10.1371/journal.pone.0009684.t003
Table 4. Haplotype distribution of HSPA8 in CHD and control
group.
Haplotype * CHD Controls OR (95% CI) P value
N% N%
AGGT 850 42.37 819 40.83 1.00
GCGT 495 24.68 479 23.88 1.00(0.85, 1.17) 0.958
GCGC 317 15.80 392 19.54 0.78(0.65, 0.93) 0.006
GGAT 245 12.21 251 12.51 0.94(0.77, 1.15) 0.549
GGGT 38 1.89 28 1.40 1.31(0.80, 2.15) 0.291
Others { 61 3.04 37 1.84 1.59(1.04, 2.42) 0.031
Total 2006 100 2006 100 -- --
*Polymorphic bases were in 39 to 59 order and from left to right the order is
rs1461496, rs10892958, rs2276077 and rs2236659.
{Other haplotype includes ACGT, GGGC, AGGC, AGAT, GCAT, ACGC, AGAC, GGAC,
ACAC,a n dACAT with frequency ,1.0%.
doi:10.1371/journal.pone.0009684.t004
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matched controls. All enrolled subjects were unrelated ethnic Han
Chinese. CHD cases were enrolled from three hospitals (Tongji
Hospital, Union Hospital, and Wugang Hospital) in Wuhan
(Hubei, China) between May 2004 and October 2006. These cases
were diagnosed according to WHO criteria or by coronary
angiography (significant coronary artery stenoses $50% in at least
one major coronary artery). Myocardial infarction was diagnosed
by a representative set of ECG, cardiac enzyme values, and typical
symptoms. Angina was defined as use of nitroglycerine, experience
of typical chest pain, or ECG changes compatible with ischemic
heart disease. In total, 1,078 patients diagnosed as having CHD
were recruited; 1,003 of them (93.0%) consented to participate in
the study and provided questionnaire information and blood
samples. The control subjects resided in the same city as the cases
and were judged to be free of CHD and peripheral atherosclerotic
arterial disease by medical history, clinical examinations, and
electrocardiography. The response rate for the controls was 92.4%
(1,003 of 1,085). Sociodemographic information, past history,
family history of cardiovascular disease, and lifestyle factors were
obtained through questionnaire interview.
Subjects were classified as nonsmokers, former, or current
smokers. Habitual physical activity was classified into four groups:
little, light, moderate and vigorous. Subjects were considered to be
hypertensive if their systolic blood pressure was $140 mmHg
and/or diastolic pressure $90 mmHg or if they were already
being treated with antihypertensive drugs. All subjects gave written
consent after receiving a full explanation of the study. The Ethics
Committee of Tongji Medical College approved this study.
Genotyping of HSPA8 Polymorphisms
Fasting venous blood was collected in 5 ml heparin tubes, and
genomic DNA was isolated with a Puregene kit (Gentra Systems,
Inc., Minneapolis, MN, USA). Genotyping was performed with
TaqMan SNP allelic discrimination method on an ABI 7900HT
real-time quantitative polymerase chain reaction (PCR) system
(Applied Biosystems), in 384-well format. PCR reactions were
carried out in reaction volume of 5 ml containing 5 ng DNA,
2.5 ml2 6 TaqMan universal PCR Master Mix, No AmpErase
UNG (Applied Biosystems), 0.125 ml4 0 6 Assay Mix (Applied
Biosystems). PCR conditions included 95uC for 10 min followed
by 40 cycles of 15 s at 92uC and 1 min at 60uC. Two blank
controls (DNA hydration solution) and two replicate quality
control samples were included in each 384-well format, and two
replicate samples were genotyped with 100% concordance. The
intensity of each SNP met the criteria of three clear clusters in two
scales generated by SDS software (Applied Biosystems). The
TaqMan primers and probes are displayed in Table S2. Finally,
genotyping failed in 13 (1.30%), 9 (0.90%), 11 (1.10%) and
24 (2.40%) controls and 38 (3.80%), 33 (3.3 0%), 36(3.60%)
and 44 (4.40%) cases in rs1461496, rs10892958, rs2276077 and
rs2236659 locus respectively owing to DNA quantity or quality.
Reporter Plasmids Construction
Because rs2236659 (-357T/C) was associated with CHD risk
and located in the core promoter region of HSPA8, we evaluated
whether this variant had allele-specific effect on its transcriptional
activity. We constructed plasmid containing 3 promoter SNPs
(rs2236660 [-703T/C], rs2236659 [-357T/C], and rs2236658
[-308A/G]). Firstly, we amplified the -1 to -780 promoter region
of the HSPA8 gene, and then inserted it into Kpn I/Hind III
enzyme sites of pGL3-Basic (Promega, Madison, Wisconsin, USA).
The first constructed plasmid contained the T-T-A haplotype
(from left to right: -703T/C, 357T/C, and -308A/G) of HSPA8
(Figure 3). Primer pairs of amplification and site-specific
mutagenesis are listed in Table S3. The direction and sequence
authenticity of the above constructs were validated by restriction
analysis and direct sequencing.
Transient Transfection and Luciferase Reporter Assays
Human umbilical vein endothelial cells (HUVEC) and human
bronchial epithelial cells (HBE) with density of 6610
4 were
seeded into 48-well plates and transfected with 100 ng pGL3-
Basic plasmids or its constructs (defined as -703T/-357T/-308A,
-703T/-357T/-308G, -703T/-357C/-308G, and -703C/-357C/
-308G) and 1 ng pRL-SV40 (Promega) using Lipofectamine 2000
(Invitrogen, Carlsbad, California, USA) when grown to 70%
confluence. Luciferase activity was measured at 24-hr using Dual-
Luciferase Reporter Assay System (Promega) on a TD-20/20n
luminometer (Turner Design, Promega). Each construct was tested
in triplicates and the transfection experiments were performed
three times independently. The results are denoted as relative
luciferase activity (RLA) since the luciferase activity was normal-
ized by Renilla luciferase activity and the empty pGL3-Basic
vector.
Biological Variables Determination
Fasting blood glucose (FBG), total cholesterol (TC), and tri-
glyceride (TG) were assayed using standard laboratory procedures
Figure 3. Effects of haplotypes in promoter of HSPA8 on
luciferase activity. Transient luciferase reporter gene expression
assays with constructs containing different haplotypes of HSPA8
promoter in human bronchial epithelial cells (HBE) and human umbilical
vein endothelial cells (HUVEC). Upper: schematic representation of
different reporter gene constructs. Variants of -703C/T, -357C/T, and
-308A/G represent rs2236660, rs2236659, and rs2236658 respectively;
Lower: luciferase expression of these constructs. All constructs were
cotransfected with pRL-SV40 to standardize the transfection efficiency.
Fold increase of luciferase activity was calculated by defining the
activity of the empty pGL3-Basic vector as 1. All experiments were
performed in triplicates at least in three independent transfection
experiments and each value represents mean (standard deviation). *and
{ indicated that P,0.05, compared with each of the construct.
doi:10.1371/journal.pone.0009684.g003
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Statistical Analysis
A chi-square test was applied to compare categorical variables
and the Hardy-Weinberg equilibrium of the polymorphisms. A
multiple logistic regression analysis was used to evaluate the
association between SNPs and CHD with appropriate adjustment
of cardiovascular risk factors. The ANOVA test was used to
examine the differences in luciferase reporter gene expression. The
linkage relationship between the four SNPs in HSPA8 gene was
measured by the linkage disequilibrium (LD) coefficient (D’)
calculating by JLIN[25] and LDA program[26]. The htSNPer1.0
software was used to select tagSNPs in HSPA8gene[11]. All
genotype data for each sample were taken to construct the
haplotypes by using the PHASE 2.0 program[13]. P,0.05 was
considered statistically significant. All data analyses were carried
out using SPSS 12.0 software (SPSS Inc., Chicago, Illinois, USA).
Power calculations were performed using Quanto 1.2.3 (available
from http://hydra.usc.edu/gxe).
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